Kolon Life Science Balance Sheet Health
Financial Health criteria checks 1/6
Kolon Life Science has a total shareholder equity of ₩137.7B and total debt of ₩107.2B, which brings its debt-to-equity ratio to 77.9%. Its total assets and total liabilities are ₩309.4B and ₩171.8B respectively.
Key information
77.9%
Debt to equity ratio
₩107.24b
Debt
Interest coverage ratio | n/a |
Cash | ₩7.56b |
Equity | ₩137.67b |
Total liabilities | ₩171.76b |
Total assets | ₩309.44b |
Recent financial health updates
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26Recent updates
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns
Jan 18Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26Financial Position Analysis
Short Term Liabilities: A102940's short term assets (₩105.0B) do not cover its short term liabilities (₩128.3B).
Long Term Liabilities: A102940's short term assets (₩105.0B) exceed its long term liabilities (₩43.4B).
Debt to Equity History and Analysis
Debt Level: A102940's net debt to equity ratio (72.4%) is considered high.
Reducing Debt: A102940's debt to equity ratio has increased from 72.9% to 77.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A102940 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A102940 has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.2% each year.